Skip to main content
. 2009 Apr;58(4):773–795. doi: 10.2337/db09-9028

FIG. 17.

FIG. 17.

Summary of studies examining the effect of TZDs versus placebo or versus active-comparator on A1C in type 2 diabetic subjects (167,168,260,268273). See text for a more detailed discussion. PIO, pioglitazone; ROSI, rosiglitazone.